A strategy for generating diverse collections of small molecules has been developed that features a multicomponent assembly process (MCAP) to efficiently construct a variety of intermediates possessing an aryl aminomethyl subunit. These key compounds are then transformed via selective ring-forming reactions into heterocyclic scaffolds, each of which possesses suitable functional handles for further derivatizations and palladium-catalyzed cross coupling reactions. The modular nature of this approach enables the facile construction of libraries of polycyclic compounds bearing a broad range of substituents and substitution patterns for biological evaluation. Screening of several compound libraries thus produced has revealed a large subset of compounds that exhibit a broad spectrum of medicinally-relevant activities.
Introduction:
The wide range of human health disorders that lack effective agents for pharmaceutical intervention has engendered innovative approaches to creating molecular libraries for biological interrogation.
These advances, coupled with the advent of high-throughput screening (HTS) technologies, has expedited the identification of novel chemical entities for development into drug leads or chemical probes to study biological systems. 1 For many years, screening decks used in HTS have been populated with compounds prepared through "combinatorial chemistry" methods, the origins of which can be traced back to Merrifield's pioneering work in which solid-phase synthesis was utilized to prepare polypeptides more efficiently and in higher purity than traditional coupling methods performed in solution. 2, 3 Building upon Merrifield's work, the "split-mix" protocol 4 was introduced as a strategy to prepare large peptide libraries, after which the "one bead, one-peptide" concept 5 was reported as a means for rapidly identifying and sequencing bioactive peptides. This technology, which utilizes parallel synthesis and enables the convenient distribution of intermediates, was later extended to the synthesis of small molecule libraries, either as mixtures or as pure compounds, whereby matrices of reagent reservoirs are mixed and matched to produce the maximum number of unique chemical outputs.
The pharmaceutical industry adopted combinatorial chemistry and related methods as outlined generally in Figure 1 beginning in the 90's in hopes of expediting the drug discovery process and lead generation; however, larger screening libraries did not equate to an increase in the number of therapeutic leads as expected. 6 In retrospect, the disappointing output from the combinatorial chemistry era taught the scientific community that screening decks comprised of randomly generated molecules tend to suffer from low hit rates and poor specificity, 7 a consequence stemming from non-optimal molecular parameters 8, 9 and inadequate structural diversity. Accordingly, screening libraries evolved from relatively simple compound sets constructed from readily available building blocks, a so-called "strength in numbers" approach, 10 to judiciously designed assortments of drug-like collections that are characterized by relatively improved hit rates and lower attrition during subsequent development efforts.
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Figure 1
Typical combinatorial chemistry approach to hit identification.
Various strategies for creating novel collections of small molecules with potentially valuable biological properties have been reported, 12 ,13 with biology-oriented synthesis (BIOS) 14 and diversity-oriented synthesis chemical inputs in a single step. 20 The potential to quickly access versatile intermediates, coupled with the efficiency and operational simplicity associated with such transformations, has inspired the development of a multitude of MCRs. 21 MCRs that are compatible with a broad range of functional groups are especially valuable because they present an opportunity for performing a variety of post-MCR transformations, such as cyclizations and refunctionalizations. 12, 22 The sequencing of MCRs with subsequent ring-closing reactions is commonly referred to as the build/couple/pair strategy, 23 and its use has led to the generation of diverse heterocyclic scaffolds in short synthetic sequences.
Some years ago we became interested in developing improved strategies for discovering novel, bioactive compounds as a consequence of our discovery of a novel multicomponent reaction in which an imine, an acylating agent, and a π-nucleophile are combined in a vinylogous Mannich reaction to give intermediates that could be quickly elaborated into alkaloid natural products. For example, the key step in our synthesis of the pentacyclic indole alkaloid oxogambirtannine (5) involved a three-component assembly process in which the Scheme 1 Total synthesis of oxogambirtannine 5.
dihydro-β-carboline 1, the acid chloride 2, and the vinyl ketene acetal 3 were combined to give adduct 4 (Scheme 1). An intramolecular Diels-Alder reaction followed by spontaneous extrusion of CO 2 and subsequent oxidation completed the three step synthesis of oxogambirtannine (5). 24, 25 The power of such three-component assembly processes is further illustrated by the reaction of the dihydro-β-carboline 1 with 1-trimethylsilyloxybutadiene (6) in the presence of crotonyl chloride (7) to deliver 8. An intramolecular hetero Diels-Alder reaction transformed 8 into 9, a key intermediate in extraordinarily concise syntheses of the heteroyohimboid alkaloid tetrahydroalstonine (10) and the corynantheoid alkaloid geissoschizine (11) (Scheme 2). The dramatic ease with which these three-component processes gave access to the complex heterocyclic frameworks found in biologically active alkaloids suggested that they might be easily adapted to develop a useful strategy for the preparation of diverse collections of small molecules. We envisioned that the strategic combination of certain aspects from BIOS and DOS would enable the assembly of such libraries via similar multicomponent assembly processes (MCAPs) (Scheme 4). MCAPs are differentiated from traditional MCRs and other domino or cascade processes 27 in that the reactants must be combined, at least in part, in a specific order rather than all at once to ensure selective chemical transformations. 12, 28 In particular, we envisioned a MCAP in which aryl aldehydes 12 and primary amines 13 are first combined to give intermediate imines that then undergo reactions with acylating (or alkylating) agents 14 and nucleophiles 15 to give intermediate aryl aminomethyl derivatives 16. It is noteworthy that aryl aminomethyl substructures in 16 are well-represented in natural products and many classes of medicinally-relevant therapeutics. 29 The four inputs in the MCAP may be programmed for further manipulation by the presence of orthogonal functional groups that can be paired in selective ring forming reactions to increase skeletal complexity and generate a series of target scaffolds 17. For example, an aryl aldehyde might bear a variety of functional groups, including chloro, bromo, azido, and carboxyl. Carbon-carbon double and triple bonds might be easily incorporated into the amines and the acylating agents, and the nucleophiles could be functionalized organometallic reagents or a number of different π-nucleophiles. After the ring-forming reactions have been performed, the remaining functional groups on the heterocyclic scaffolds 17 may be used in cross-coupling and other functional group transformations to increase structural diversity and provide diverse compound collections 18 that maximally populate chemical space. The Although the seeds for this novel entry to small compound collections had been sown during our efforts in alkaloid total synthesis, these concepts lay fallow until there was a motivation to develop the approach. The inspiration to access sets of structurally diverse, drug-like compounds for biological screening came with our Figure 2 Tested scaffolds with confirmed biological activity.
MCAP followed by Dipolar Cycloadditions
Dipolar cycloadditions have long been employed to construct heterocyclic subunits that comprise both natural products and non-natural pharmaceutical agents. 30 In a simple variant of this approach, the brominated scaffold 39 was obtained through a reductive amination of bromoaldehyde 38 and subsequent thermally-induced dipolar cycloaddition (Scheme 5). The aryl bromide and the secondary amine in 39 were both obvious embarkation points from which analogs for biological evaluation could be obtained by cross-coupling and N-derivatization reactions, respectively. Treatment of amine 39 with electrophiles, such as phenethyl isothiocyanate 40, gave quick access to a range of benzodiazepine analogs, including thiourea 41. Alternately, palladium catalyzed arylations were attractive reactions for installing aryl groups on the nitrogen atom and the aryl bromide of 39 to afford biaryl derivatives as typified by 44. The 1,4-benzodiazepine ring system is present in a large number of pharmaceuticals, of which alprazolam (45) is a notable example as it is reported to be the most prescribed psychotropic drug in the Unites States ( Figure 3 ). 38 1,4-Benzodiazepines are potent binders of GPCRs and ligand-gated ion channels 39 and are recognized as prominent frameworks in medicinal chemistry. 40 Significantly, the triazolobenzodiazepines generated with the synthetic transformations described in schemes 4 and 5 represent novel members of the benzodiazepine class, the screening of which has led to the discovery of a number of compounds having diverse biological activities. For example, the α-amidonitrile 36 (Scheme 4) was identified as an inhibitor of 5-meCpG- Screening efforts also revealed that benzodiazepine 44 (Scheme 5) possessed inhibitory activity towards Nlinked glycosylation (NLG), a protein modification process that is critical to the stability and proper folding of transmembrane proteins. 45, 46 Receptor tyrosine kinases are a subclass of N-glycosylated enzymes that are implicated in neoplastic development and resistance to chemotherapies. The drug tunicamycin reduces protein tyrosine kinases via NLG, yet its use as a therapeutic agent is limited due to hepatotoxicity. 47 Hits identified in this screen may aid the development of novel, non-toxic NLG inhibitors as potential chemotherapeutic agents that improve outcomes in radiation therapy.
HTS screening revealed the thiourea 41 (Scheme 5) to be an inhibitor of fatty acid synthase (FAS), 48 an enzyme that is overexpressed in a variety of cancer cell types and is essential for the growth of solid tumors. 49 As there are no known inhibitors of the thioesterase domain of FAS, efforts are underway to discover novel small molecules with inhibitory activity towards this subunit of the enzyme. Novel FAS inhibitors will serve as tools to probe the therapeutic potential of FAS modulation.
An azide/alkyne cycloaddition also served as a key step for preparing other bioactive scaffolds. For example, employing metal acetylides as nucleophilic partners in MCAPs affords intermediates that can be quickly elaborated into polycyclic ring systems through an azide/alkyne cycloaddition. We found that activation of the starting imine 46 with the Lewis acid TMSOTf prior to the addition of zinc or magnesium acetylides produced intermediate N-silyl amines that underwent acylation with o-azidobenzoyl chloride (47) (Scheme 6). 50 The amides thus produced underwent a [3+2]-dipolar cycloaddition to deliver tetrahydroisoquinoline-fused triazolobenzodiazepines 48 and 49.
Scheme 6 One-pot formation of pentacycles 48 and 49. 
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∆ deficient cells but not in healthy cells suggests that a "synthetic lethal" approach may be harnessed to treat cancers arising from BRCA2 mutations. 57 Since there are no known specific inhibitors of RAD52, a screening assay was developed to identify small molecule inhibitors of RAD52 to study the inhibitory effect on human cells and ultimately, discover lead compounds that may be developed into novel therapeutics for breast cancer. Investigators within the MLPCN identified isoxazolidine 64 as a regulatory particle non-ATPase11 (RPN 11 ) inhibitor with an IC 50 by employing a zinc-metalloprotease active site. Small molecule inhibitors of RPN 11 metalloprotease are currently under investigation as novel antitumor agents, which putatively elicit their activity through inhibiting degradation of proteasome substrates resulting in stymied tumor growth.
When isoxazolidine-and pyrrolidine scaffolds contained a 2-C Ar bromine atom, a second cyclization could be utilized to provide access to fused tetracyclic ring systems. This transformation is highlighted by the sequence in Scheme 9, in which the secondary amine 65, prepared in 2 steps from aldehyde 53 (Scheme 7), was treated with 2-methoxyethyl isothiocyanate to give an intermediate thiourea 66. 53 Upon heating in the presence of Pd(tBu 3 P) 2 , S-C Ar bond formation ensued to give the 2-imino-1,3-benzothiazinane (67). In a related transformation, a mixture of 1-naphthylisocyanate, Pd(OAc) 2 , BINAP, and amine 65 was stirred at room temperature until formation of the binaphthyl urea 68 was complete, whereupon the mixture was simply heated to deliver the dihydroquinazolin-2-one 69 via an intramolecular N-arylation.
Scheme 9 Synthesis of bioactive urea derivatives 67 and 69.
Dihydroquinazolin-2-one (67) was identified as an inhibitor of protein arginine methyltransferase 1 (PRMT1) (24.2% at 2.8 µM) in a HTS assay. 59 PRMT1 is responsible for over 85% of cellular arginine methylation, and improper PRMT1 function has been linked to a range of inflammatory disorders, including asthma and certain types of cancers. 60 The identification of novel PRMT1 inhibitors will help evaluate the potential medicinal value that could be harnessed through small molecule modulation of this enzyme. 61 An MLPCN HTS for small molecule inhibitors of the phosphatidylinositol 4-phosphate 5-kinases (PI4P5K) tentatively identified 2-imino-1,3-benzothiazinane (69) as an active compound. 62 The PI4P5Ks regulate AKT signaling and tumor cell growth, 63 and recent findings have illuminated PI4P5K's potential involvement in oncogenesis, suggesting that modulating its activity may be an effective therapeutic approach to treating cancers.
A nitrone dipolar cycloaddition also served as a key step to access novel tetrahydroisoquinolines as is illustrated by the preparation of 75 (Scheme 10). The prominence of the hexahydropyridoisoquinoline motif (76) in molecules with potent biological activities, ranging from opioid antagonism 65 (77) to α 2 -adrenoceptor antagonism 66 (78) , has made compound libraries embodying this subunit an attractive screening platform for identifying hits that may be advanced to drug leads ( Figure 4 ). HTS of a set of hexahydropyridoisoquinoline analogs identified urea 75 as a 2.0 µM inhibitor of hepatitis C virus (HCV), 67, 68 for which the standard line of treatment utilizes pegylated interferon and ribavirin, which has significant adverse side effects and is curative in only 40-75% of patients. 69 The hexahydropyridoisoquinoline ring system may thus serve as a template for the discovery of novel small molecule inhibitors of HCV that have more favorable side-effect profiles. In an extension of our work with dihydroisoquinolines (e.g., Scheme 10), we examined the feasibility of using functionalized dihydro-β-carbolines as starting materials for MCAPs that would give intermediates suitable for subsequent elaboration via nitrone dipolar cycloadditions. The MCAPs using 79 and 80 were conducted in a fashion to give the aldehydes 81 and 82, but in this case the use of TMSOTf was not required (Scheme 11). Owing to the well-known, potent and diverse biological activities of members of the Yohimbine and Corynanthe class of alkaloids, 72 it was not surprising that screening of collections of analogs of 10 and 11 (Scheme 2) exhibited potentially useful biological properties. For example, N-methylbenzylamine 86 (Scheme
11)
73 is a potent inhibitor of Trypanosoma brucei methionyl tRNA synthetase (T. brucei MetRS), an enzyme critical to the etiological agent of human African trypanosomiasis (HAT; sleeping sickness). 74, 75 There is an unmet need for effective therapeutic agents for African trypanosomiasis, because currently available drugs possess high toxicity, lack good oral bioavailability, or require difficult dosing regimens. 76 As small molecule inhibition of
MetRS is regarded as a viable treatment approach for this neglected tropical disease, 75 N-methylbenzylamine 86 may be an attractive starting point for the development of improved drugs that combat HAT.
MLPCN screening identified N-methylamino alcohol 87 (Scheme 12) as an orthopoxvirus inhibitor with an IC 50 of 12.6 µM. 77 The eradication of smallpox and subsequent discontinuation of routine vaccinations has resulted in populations with attenuated immunity towards orthopoxviruses, of which monkeypox and smallpox are members. 78 This, compounded with the lack of a single FDA-approved drug to treat infected individuals, has spurred efforts to identify orthopoxvirus inhibitors. 79 As such, novel small molecule viral inhibitors such as 87 may help guide the development of much needed therapeutic agents for monkeypox.
MCAP Followed by Ring-Closing Metathesis (RCM) and Other Ring-Forming Reactions
The piperidine and homopiperidine ring systems figure prominently into pharmaceuticals and biologically active natural products. 80, 81 Constructing scaffolds embodying these motifs thus seemed to be an attractive approach for accessing molecular libraries for biological evaluation. We found that 2-aryl substituted derivatives of these azacycles could quickly be prepared through a MCAP / RCM reaction sequence when the MCAP was conducted with inputs containing unsaturated functionality. 82 In this variation of the MCAP, the amine and nucleophile reagents possess carbon-carbon double bonds that render products that can be cyclized by a RCM reaction to form tetrahydropyridines and tetrahydroazepines. Significantly, functionality resident in the metathesis products enable a range of subsequent ring forming reactions that provide structurally diverse, polycyclic frameworks. Representative examples of the application of these concepts that led to the discovery of collections of novel bioactive compounds are outlined herein.
a. Elaboration of RCM Products via Heck Cyclizations.
In early accounts, we showed that tetrahydropyridines prepared by RCM of dienes formed by selected MCAPs could be cyclized by Heck reactions to give bridged polycyclic systems. 31, 32 A straightforward modification of this methodology using dihalo aldehydes 88 and 89 83 as inputs together with allylamine, benzyl chloroformate, and allylzinc bromide afforded the dienes 90 and 91, respectively (Scheme 13). 84, 85 Cyclizations of these compounds via RCM to give the corresponding tetrahydropyridines 92 and 93 were induced using Grubbs II catalyst. A simple modification of the sequence depicted in Scheme 13 allowed for a facile entry to the homonorbenzomorphan scaffold. In the event, the MCAP involving benzaldehyde 98 89 Moreover, the carbamate 108 was found to be a potent acetylcholinesterase (AChE) inhibitor, leading to significant ACh elevation in mouse forebrain. 92 The documented biological activities associated with these azabicycles, coupled with their lack of overt toxicity in animal models, suggest that these scaffolds may be harnessed for the discovery and development of novel medicinal agents. neuroprotection towards amyloid-β peptide 94 and anti-amnesic effects in rodents infused with amyloid-β peptide. 95 Indeed, sigma 1 receptor modulators are commanding increasing interest as potential therapeutics for neuropathic pain, substance abuse and amyotrophic lateral sclerosis (ALS). 96 Continued development of reaction between an aryllithium that is generated via lithium-halogen exchange and a pendant electrophilic center. 104 It thus occurred to us that the N-acyl tetrahydropyridine 93 might undergo the Parham cyclization to produce isoindolinones, so we explored the feasibility of applying this reaction to the synthesis of a collection of novel isoindolinones. Indeed, we discovered that 93 underwent selective halogen-metal exchange upon treatment with n-BuLi, and spontaneous cyclization ensued to form isoindolinone 113 (Scheme 18). 84 Reduction of 113 with Adam's catalyst (PtO 2 ) delivered the reduced scaffold 114 with no observed loss of halogen. Both biaryl and aniline derivatives were prepared through cross-coupling reactions with aryl chloride 114. In one instance, a Buchwald-Hartwig cross-coupling reaction between isoindolinone 114 and piperazine generated the aniline derivative 115, which contains a secondary nitrogen atom that could be functionalized to prepare a set of analogs. Significantly, isoindolinone 115 bears structural similarity to known cyclin-dependent kinase (CDK)/glycogen synthase kinase (GSK) 3 inhibitors, collectively termed valmerins (i.e., tetrahydropyrido-[1,2-a]isoindolone (heteroaryl)ureas ( Figure 6 ). 105 Many members from this class inhibit CDK5 and GSK3 with an IC 50 < 100 nM.
More importantly, isoindolinone 116 not only exhibited sub-micromolar activity towards various human cancer cell lines, but also inhibited tumor growth in HCT-116 mouse xenograft models without overt toxicity. 105 It is . 107 Small molecule CendR agonists may thus represent potential tools for introducing compounds into tissues, whereas antagonists could limit tissue penetration of toxins and inflammatory agents that use the CendR pathway.
In addition to the specific case studies presented in previous sections of this account, we have applied the fundamental principles summarized herein to synthesize a broad spectrum of other novel small molecules having natural product-and drug-like scaffolds. For example, a number of polyheterocyclic compounds, 
Summary and Conclusion.
The foregoing survey reveals that the modular nature of the MCAP outlined in Scheme 3 enables rapid entry to a multitude of versatile intermediates that can be advanced via numerous ring-closing transformations to generate a variety of heterocyclic ring scaffolds. Functionality embedded in the starting inputs, or unmasked at a later stage, allows the subsequent preparation of collections of analogs bearing diverse substituents within each scaffold class. Screening these collections of small molecules has already led to the identification of compounds that exhibit a broad range of biological activities. Some of these will likely serve as tools to probe biological function and mechanism, whereas others may be further developed as therapeutic agents for treating neurodegenerative and infectious diseases and a range of human cancers. In this context, it is noteworthy that application of guidelines set forth by Lipinski 8 and Veber 9 reveals that a majority of the compounds we have created possess physicochemical parameters that are associated with favorable oral bioavailability. Accordingly, some of these compounds are attractive candidates for analog design and advancement from hit to drug lead and beyond. 108 Indeed, a number of compounds derived from hits that were generated by implementing the strategy outlined herein are currently undergoing preclinical development. These promising findings augur well for future applications of this approach to access sets of drug-like small molecules with activities against diverse biological targets.
